Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 5 ... According to a study from the United States, "The anti-tumor properties of thalidomide or in combination with an oncolytic herpes virus (OncdSyn) was investigated in a mouse ...
2009 NOV 9 ... analog, the monoclonal antibodies anti-CD20 ofatumumab and the anti-CD23 lumiliximab, thalidomide and its analog lenalidomide, the semi-synthetic flavonoid flavopiridol and other agents ...
2009 OCT 5 ... According to recent research from Winchester, the United Kingdom, "Thalidomide, one of whose activities is to inhibit Tumour Necrosis Factor (TNF)-alpha production, ...
2009 OCT 12 ... "Although the increased risk of venous thrombotic events with thalidomide in multiple myeloma (MM) has been well described, an association with an increased risk ...
2009 OCT 5 ... dialysis." "The aim of the present study was to evaluate the effect of thalidomide, which is used for the treatment of various inflammatory and autoimmune diseases, on the ...
2009 NOV 23 ... into the coronary vessel wall." "We sought to investigate the effects of Thalidomide (Th), a potent anti-angiogenic drug on vasa vasorum (VV) neovascularization, vessel wall ...
2009 NOV 2 ... mono-therapy or in combination with cyclophosphamide, nucleoside analog, bortezomib, or thalidomide-based regimens can be considered for the first-line therapy of WM and should take into ...
2009 NOV 23 ... New research, 'Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma,' is the subject of a report. "The expanded ...
2009 OCT 12 ... multiple myelomas, other drug regimens have been successfully applied, including thalidomide treatments." "Besides its well-documented anti-angiogenic effects,...
2009 NOV 16 ... benefit from supportive care, but a specific subgroup responds particularly well to oral thalidomide analogues," wrote K. Vanpuyvelde and colleagues. The researchers ...
2009 SEP 21 ... and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance ...
2009 OCT 12 ... Myeloma, Myeloma, Nephrology, Oncology, Pharmaceuticals, Renal Function, Revlimid, Thalidomide, Therapy, Treatment, University of Athens. This article was prepared by ...
2009 SEP 14 ... the mTOR inhibitor temsirolimus, immunomodulatory and antiangiogenic agents including thalidomide and lenalidomide, and cyclin-dependent kinase inhibitors, as well as a renewed interest ...
2009 SEP 14 ... assessed the clinical activity of neoadjuvant therapy with carboplatin, gemcitabine, and thalidomide in patients with stage IIB to IIIA non-small cell lung cancer (NSCLC). A secondary goal ...
2009 SEP 28 ... a median of 7 prior regimens (range, 3-13), including autologous transplantation in 20, thalidomide in all 23, lenalidomide in 17, and bortezomib in 19, 9 of whom were ...
2009 OCT 12 ... the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and ...
2009 NOV 2 ... in resistin were noted among any patients. In patients with relapse and treated with thalidomide, no particular adipokine pattern was revealed. Leptin induced the expression of several ...
